Business Wire

Invitae Announces Major Expansion of Its Test Menu for Neurological, Pediatric, and Rare Genetic Conditions and Introduces New Panels for Inherited Metabolic Disorders and ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...
Nasdaq

Can Invitae Be the Winner-Take-Most in Genetic Testing?

What is a winner-take-most market? The long term profitability and success of any company is highly dependent on the market in which it operates. Many markets have low barriers to entry; many sellers ...
MedCity News

Invitae’s First of Its Kind Cancer Test Receives FDA Marketing Authorization

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
News Medical

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
News Medical

Invitae introduces new patient pay program to make genetic testing more affordable, accessible

Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price ...
Business Wire

Invitae Expands Its Neuromuscular Offering with Broad, Affordable Panels and New Testing Categories for Patients

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it now offers genetic testing for neuromuscular diseases, including Duchenne/Becker ...
Benzinga.com

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...
Business Insider

Invitae announces expansion of its genetic test menu with addition of new tests and expanded panels for inherited metabolic and immune system disorders, including panels to ...

SAN FRANCISCO, April 20, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced the addition of 80 new panels alongside ...
Nasdaq

Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium

SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer ...
The Motley Fool

Can telemedicine save the day?

Invitae has embarked on an ambitious mission to bring medical-grade genetic testing to the masses. By increasing the quality of the data collected compared to consumer ancestry tests, the company has ...
The Motley Fool

Could Invitae Stock Help You Retire a Millionaire?

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. Invitae is in the ...